Immatics Announces First Patient Treated with ACTengine IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo (nivolumab) in Patients with Advanced Solid Tumors

The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab1, a PD-1 immune checkpoint inhibitor

Related Keywords

Germany ,Houston ,Texas ,United States ,Twitterand Linkedin ,Cedrik Britten ,Anja Heuer ,Bristol Myers Squibb ,Immatic Actengine ,Instagram ,Corporate Communications ,Bristol Myers Squibb Company ,Trophic Communications ,Research Institute Of Texas ,Chief Medical Officer ,Myers Squibb ,Response Evaluation Criteria In Solid Tumors ,All Immatic ,Stem Cell Therapeutics Research Laboratory ,Cancer Prevention ,Research Institute ,Adoptive Cell Therapies ,Looking Statements ,Investor Relations ,Immatics ,Nnounces ,First ,Patient ,Reated ,Actengine ,Ma203 ,Combination ,Checkpoint ,Inhibitor ,Opdivo ,Nivolumab ,Patients ,Dvanced ,Olid ,Rumors ,